Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pelikan bags $69m for diabetes monitoring technology:

This article was originally published in Clinica

Executive Summary

Palo Alto, California-based Pelikan Technologies is to take its Pelikan Sun electronic lancing device to the US after raising $89m through a series F equity financing and a venture loan facility. The series F round, which raised $69m, was led by Clarus Ventures. The $20m debt financing was provided by General Electric Capital and Oxford Finance. The Pelikan Sun has been approved by the FDA and was recently launched in Australia and Europe. Its US debut is slated for the first quarter of 2008. Pelikan Technologies said it will also use the new capital to complete development of its next-generation, fully-integrated blood glucose system and finance the launch of the product, which is also expected next year.

You may also be interested in...



COVID-19: ResMed Ramps Up CPAP, BPAP Manufacturing To Address Ventilator Shortage

ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage. 

Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

Topics

UsernamePublicRestriction

Register

MT050412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel